Navigation Links
Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
Date:3/3/2008

LEXINGTON, Mass., March 3 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that Glenn L. Cooper, M.D. plans to retire as Indevus' Chief Executive Officer and Chairman of the Board of Directors later this year on or prior to September 1, 2008.

Dr. Cooper said, "After 15 years at the helm of the company and at the age of 55, I feel the time is right for me to retire from this marvelous company. Over the years, we have successfully developed and commercialized innovative products and have built a specialty pharmaceutical company tightly focused on urology and endocrinology. We have a strong capable senior management team and employee group who has accomplished great things on the clinical, regulatory, business development, legal, manufacturing and commercialization fronts. With five products on the market and two more anticipated product launches later this year, I believe the company is poised for its next phase of success leading to profitability. I regard the anticipated future approval of NEBIDO(R) as a fitting capstone to my tenure at the company and I intend to see the regulatory process through to its conclusion."

Cheryl Morley, presiding director and chairman of Indevus' Nominating and Governance Committee said, "The Board is extremely appreciative of Glenn's long and effective service and we are sorry to see him depart. We intend to recruit an experienced pharmaceutical executive capable of managing a growing and complex commercial company. Glenn has built a talented team of senior executives and we expect that the transition to a new CEO will be seamless."

Indevus and Dr. Cooper have entered into an Executive Retirement Agreement pursuant to which Dr. Cooper shall maintain his position as Chief Executive Officer and Chairman of the Board of Indevus until the earlier of September 1, 2008 or Indevus' hiring of a replacement Chief Executive Officer. Following his retirement, Dr. Cooper plans to serve as an advisor to Indevus for twelve (12) months thereafter.

Indevus has commenced efforts to evaluate and retain a successor Chief Executive Officer.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA XR(TM) and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. Indevus undertakes no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise.

Contact:

For Indevus:

Michael W. Rogers

Executive Vice President and CFO

(781) 861-8444

Brooke D. Wagner

Vice President, Corporate Communications

(781) 402-3410


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
3. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
4. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: